A WORLD LEADER IN RIBOSOME TARGETED GENETIC THERAPIES

NONSENSE MUTATION RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) and JUNCTIONAL EPIDERMOLYSIS BULLOSA (JEB)

Epidermolysis bullosa (EB) is a group of rare inherited skin disorders that cause the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters.1

RDEB and JEB are the two main types of EB.

  • RDEB is caused by mutations in the COL7A1 gene that codes for COL7A1 protein. The COL7A1 gene is involved in coding for the collagen that helps attach the epidermis to underlying layers of skin. We are targeting nonsense mutations in COL7A1. These represent approximately 30-40% of all mutations in COL7A1.
  • JEB is most commonly caused by mutations in the LAMA3, LAMB3 and LAMC2 genes. The LAMA3, LAMB3, and LAMC2 genes are involved in coding for a protein that plays an important role in strengthening and stabilizing the skin. We are targeting nonsense mutations in LAMB3 genes that represent approximately 70% of all mutations.

Pipeline

Infants are typically born with widespread blistering and areas of missing skin, often caused by trauma during birth

Pipeline

Most RDEB patients develop skin cancer by age 35

Pipeline

Average mortality of patients with JEB is 18 months

Pipeline

Affects ~4,000 patients worldwide with nonsense mutations

Pipeline

There are no approved treatments; management is palliative

ZKN-013 is our lead TURBO-ZM™ based molecule in our program to address nonsense mutations in RDEB/JEB.

Existing data paved the way for clinical development

  • Supported by clinical results with gentamicin
    • Patients treated with gentamicin (vs those treated with placebo) had
      ~70% increase in wound closure and ~70% decrease in blistering events

COL7 IN TREATED RDEB PATIENT KERATINOCYTES*

Organoid Swelling Charts

Preclinical Results

Preclinical results support that RMAs can restore
functional collagen protein at levels comparable
to high-dose gentamicin

Reference: 1. Genetics home reference: dystrophic epidermolysis bullosa. National Institutes of Health: US National Library of Medicine. https://ghr.nlm.nih.gov/condition/dystrophic-epidermolysis-bullosa#genes. Accessed June 17, 2021.